• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives.非透析慢性肾脏病患者贫血的管理:当前建议、实际做法和患者观点。
Kidney360. 2020 Jul 1;1(8):855-862. doi: 10.34067/KID.0001442020. eCollection 2020 Aug 27.
2
Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.透析慢性肾脏病患者贫血的经济和生活质量负担:系统评价。
J Med Econ. 2019 Jun;22(6):593-604. doi: 10.1080/13696998.2019.1588738. Epub 2019 Mar 27.
3
Associations of Hemoglobin Levels With Health-Related Quality of Life, Physical Activity, and Clinical Outcomes in Persons With Stage 3-5 Nondialysis CKD.血红蛋白水平与 3-5 期非透析 CKD 患者健康相关生活质量、体力活动及临床结局的相关性。
J Ren Nutr. 2020 Sep;30(5):404-414. doi: 10.1053/j.jrn.2019.11.003. Epub 2020 Jan 21.
4
Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
.FIND-CKD试验中未接受透析治疗的慢性肾脏病患者对口服铁剂的红细胞生成反应
Clin Nephrol. 2017 Dec;88(12):301-310. doi: 10.5414/CN109198.
5
Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia.血清铁储存标志物与非透析依赖的慢性肾脏病患者(无论是否合并贫血)的身体健康相关生活质量较差相关。
Nephrol Dial Transplant. 2021 Aug 27;36(9):1694-1703. doi: 10.1093/ndt/gfab050.
6
7
2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.2008年日本透析治疗学会:慢性肾脏病肾性贫血指南
Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.
8
A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD.一项比较静脉注射蔗糖铁与口服铁剂治疗非透析依赖型慢性肾脏病贫血患者的随机对照试验。
Kidney Int. 2005 Dec;68(6):2846-56. doi: 10.1111/j.1523-1755.2005.00758.x.
9
Is there an established hemoglobin target range for patients undergoing chronic dialysis?对于接受长期透析的患者,是否有既定的血红蛋白目标范围?
Semin Dial. 2018 Jul;31(4):415-419. doi: 10.1111/sdi.12683. Epub 2018 Mar 6.
10
Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.静脉补铁与口服补铁治疗 CKD 贫血的疗效比较:一项更新的系统评价和荟萃分析。
Am J Kidney Dis. 2016 Nov;68(5):677-690. doi: 10.1053/j.ajkd.2016.04.018. Epub 2016 Jun 16.

引用本文的文献

1
Association of iron deficiency with kidney outcome and all-cause mortality in chronic kidney disease patients without anemia.缺铁与非贫血慢性肾病患者肾脏结局及全因死亡率的关联
Nutr J. 2025 Jan 15;24(1):7. doi: 10.1186/s12937-025-01072-1.
2
Prevalence, risk factors, and treatment of anemia in hospitalized older patients across geriatric and nephrological settings in Italy.意大利老年医学和肾脏病学环境中住院老年患者贫血的患病率、危险因素和治疗。
Sci Rep. 2024 Aug 24;14(1):19721. doi: 10.1038/s41598-024-70644-8.
3
Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study.稳定缺氧诱导因子以治疗慢性肾脏病贫血:从基础理论到临床研究
Kidney Dis (Basel). 2024 Jan 3;10(2):132-142. doi: 10.1159/000536039. eCollection 2024 Apr.
4
Managing Anemia: Point of Convergence for Heart Failure and Chronic Kidney Disease?管理贫血:心力衰竭与慢性肾脏病的交汇点?
Life (Basel). 2023 Jun 1;13(6):1311. doi: 10.3390/life13061311.
5
Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents.评估口服低氧诱导因子脯氨酰羟化酶抑制剂瓦达司他在啮齿类动物中的致癌性。
Toxicol Pathol. 2023 Jan;51(1-2):56-60. doi: 10.1177/01926233231168836. Epub 2023 May 9.
6
Real-Life Anemia Management Among Patients with Non-Dialysis-Dependent Chronic Kidney Disease in Three European Countries.欧洲三个国家非透析依赖型慢性肾脏病患者的真实生活中的贫血管理
Int J Nephrol Renovasc Dis. 2023 Apr 13;16:115-129. doi: 10.2147/IJNRD.S401598. eCollection 2023.
7
Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease.慢性肾脏病患者对促红细胞生成素刺激剂的低反应性
Kidney Dis (Basel). 2022 Jan 14;8(2):103-114. doi: 10.1159/000521162. eCollection 2022 Mar.
8
Iron Deficiency in CKD Without Concomitant Anemia.慢性肾脏病中无合并贫血的缺铁情况
Kidney Int Rep. 2021 Aug 10;6(11):2752-2762. doi: 10.1016/j.ekir.2021.07.032. eCollection 2021 Nov.
9
The Role of Eryptosis in the Pathogenesis of Renal Anemia: Insights From Basic Research and Mathematical Modeling.红细胞凋亡在肾性贫血发病机制中的作用:来自基础研究和数学建模的见解
Front Cell Dev Biol. 2020 Dec 9;8:598148. doi: 10.3389/fcell.2020.598148. eCollection 2020.

本文引用的文献

1
Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated.慢性肾脏病预后和实践模式研究中3-5ND期慢性肾脏病患者的贫血和缺铁情况:常未得到检测,治疗方式各异
Clin Kidney J. 2019 Aug 3;13(4):613-624. doi: 10.1093/ckj/sfz091. eCollection 2020 Aug.
2
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment.慢性肾脏病中的缺铁:病理生理学、诊断和治疗的最新进展。
J Am Soc Nephrol. 2020 Mar;31(3):456-468. doi: 10.1681/ASN.2019020213. Epub 2020 Feb 10.
3
Associations of Hemoglobin Levels With Health-Related Quality of Life, Physical Activity, and Clinical Outcomes in Persons With Stage 3-5 Nondialysis CKD.血红蛋白水平与 3-5 期非透析 CKD 患者健康相关生活质量、体力活动及临床结局的相关性。
J Ren Nutr. 2020 Sep;30(5):404-414. doi: 10.1053/j.jrn.2019.11.003. Epub 2020 Jan 21.
4
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.罗沙司他治疗未接受透析的肾病患者的贫血。
N Engl J Med. 2019 Sep 12;381(11):1001-1010. doi: 10.1056/NEJMoa1813599. Epub 2019 Jul 24.
5
Patient Perspectives on the Meaning and Impact of Fatigue in Hemodialysis: A Systematic Review and Thematic Analysis of Qualitative Studies.患者对血液透析中疲劳的意义和影响的看法:系统评价和定性研究的主题分析。
Am J Kidney Dis. 2019 Aug;74(2):179-192. doi: 10.1053/j.ajkd.2019.01.034. Epub 2019 Apr 5.
6
Iron Supplementation Improves Cardiovascular Outcomes in Patients with Heart Failure.补铁可改善心力衰竭患者的心血管结局。
Am J Med. 2019 Aug;132(8):955-963. doi: 10.1016/j.amjmed.2019.02.018. Epub 2019 Mar 7.
7
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.维持性血液透析患者的静脉铁剂治疗。
N Engl J Med. 2019 Jan 31;380(5):447-458. doi: 10.1056/NEJMoa1810742. Epub 2018 Oct 26.
8
Assessing Fatigue in the ESRD Patient: A Step Forward.评估终末期肾病患者的疲劳:向前迈进的一步。
Am J Kidney Dis. 2018 Mar;71(3):306-308. doi: 10.1053/j.ajkd.2017.10.021.
9
Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018.慢性肾脏病早期和终末期肾病贫血更新:2018 年核心课程。
Am J Kidney Dis. 2018 Mar;71(3):423-435. doi: 10.1053/j.ajkd.2017.09.026. Epub 2018 Jan 11.
10
Patient-Reported Outcome Measures for Fatigue in Patients on Hemodialysis: A Systematic Review.透析患者疲劳的患者报告结局测量:系统评价。
Am J Kidney Dis. 2018 Mar;71(3):327-343. doi: 10.1053/j.ajkd.2017.08.019. Epub 2017 Dec 1.

非透析慢性肾脏病患者贫血的管理:当前建议、实际做法和患者观点。

Management of Anemia in Nondialysis Chronic Kidney Disease: Current Recommendations, Real-World Practice, and Patient Perspectives.

机构信息

DOPPS Program Area, Arbor Research Collaborative for Health, Ann Arbor, Michigan.

School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.

出版信息

Kidney360. 2020 Jul 1;1(8):855-862. doi: 10.34067/KID.0001442020. eCollection 2020 Aug 27.

DOI:10.34067/KID.0001442020
PMID:35372964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8815734/
Abstract

In nondialysis CKD (ND-CKD), anemia is a multifactorial and complex condition in which several dysfunctions dynamically contribute to a reduction in circulating hemoglobin (Hb) levels in red blood cells. Anemia is common in CKD and represents an important and modifiable risk factor for poor clinical outcomes. Importantly, symptoms related to anemia, including reduced physical functioning and fatigue, have been identified as high priorities by patients with CKD. The current management of anemia in ND-CKD (., parameters to initiate treatment, Hb and iron indexes targets, choice of therapies, and effect of treatment on clinical and patient-reported outcomes) remains controversial. In this review article, we explore the epidemiology of anemia in ND-CKD and revise current recommendations and controversies in its management. Exploring data from real-world clinical practices, particularly from the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps), we highlight the current challenges to translating current recommendations to clinical practice, providing patients' perspectives of anemia and how it affects their quality of life. Finally, we summarize recent advances in the field of anemia that may change the way this condition will be managed in the future.

摘要

在非透析慢性肾脏病(ND-CKD)中,贫血是一种多因素和复杂的病症,其中几种功能障碍会动态地导致循环血液中红细胞内血红蛋白(Hb)水平降低。贫血在 CKD 中很常见,是不良临床结局的一个重要且可改变的危险因素。重要的是,与贫血相关的症状,包括体力活动减少和疲劳,已被 CKD 患者确定为高度优先事项。目前 ND-CKD 贫血的管理(即,开始治疗的参数、Hb 和铁指标目标、治疗方法的选择以及治疗对临床和患者报告结局的影响)仍然存在争议。在这篇综述文章中,我们探讨了 ND-CKD 中贫血的流行病学,并修订了目前关于其管理的建议和争议。我们从真实世界的临床实践中探索数据,特别是从慢性肾脏病结局和实践模式研究(CKDopps)中,强调了将当前建议转化为临床实践的当前挑战,提供了患者对贫血的看法以及贫血如何影响他们的生活质量。最后,我们总结了贫血领域的最新进展,这些进展可能会改变未来对这种疾病的管理方式。